Testoni N, Martinelli G, Farabegoli P, Zaccaria A, Amabile M, Raspadori D, Pelliconi S, Zuffa E, Carboni C, Tura S
Institute of Haematology, L. e A. Seràgnoli, University of Bologna, Italy.
Blood. 1996 May 1;87(9):3822-7.
Methods of detecting minimal residual disease (MRD) in chronic myeloid leukemia (CML) include chromosome analysis, Southern blotting, polymerase chain reaction (PCR) and fluorescent in situ hybridization (FISH) techniques. We report a novel method to detect intracellular messenger RNA (mRNA) by combining the techniques of reverse transcription (RT) and PCR performed directly inside the cells, without extraction of the nucleic acid. We applied this method, which we call "in-cell RT-PCR", to detect hybrid BCR/ABL transcript within single cells. After cellular permeabilization and fixation of single cells in suspension, the neoplastic mRNA was reverse transcribed into cDNA, and the cDNA was amplified by PCR with fluorescent primers, specific for bcr/abl. Flow cytometry was used to detect cells positive for the amplified DNA within the cell cytoplasm. After transferring the amplified cells onto slides by cytospin, the positive cells for BCR/ABL cDNA were observed by fluorescent microscopy. The technique was capable of detecting low abundancy signals and distinguishing different levels of gene expression. The amplification products were found in the cells and supernatants. The distribution was critically affected by the protease digestion condition. The specificity of amplification was confirmed by a nested RT-PCR of BCR/ABL performed on extracted mRNA from the same sample, and by reamplification of supernatants. We have used the technique to study 10 Ph+ CML patients and three normal subjects as controls. Four patients were 100% Ph+ at diagnosis time and RT-PCR+ at cytogenetic and molecular analysis, respectively. In-cell RT-PCR showed that the residual non-neoplastic cells could be observed in all cases. In two patients undergoing interferon-alpha (IFN-alpha) therapy and in four bone-marrow transplanted patients, the in-cell RT-PCR was used to compare the level of Ph+ positivity detected by cytogenetic analysis with the number of cells expressing BCR/ABL transcript. In this manner, we could estimate the MRD. Our preliminary application of the technique suggests that it is capable of accurately identifying cells transcribing bcr/abl, and that it may have significant clinical applications in the detection of MRD.
检测慢性粒细胞白血病(CML)微小残留病(MRD)的方法包括染色体分析、Southern印迹法、聚合酶链反应(PCR)和荧光原位杂交(FISH)技术。我们报告了一种通过结合逆转录(RT)技术和直接在细胞内进行的PCR技术来检测细胞内信使核糖核酸(mRNA)的新方法,无需提取核酸。我们应用这种我们称为“细胞内RT-PCR”的方法来检测单个细胞内的杂交BCR/ABL转录本。在对悬浮的单个细胞进行通透化处理和固定后,将肿瘤mRNA逆转录为cDNA,然后用针对bcr/abl的荧光引物通过PCR扩增cDNA。使用流式细胞术检测细胞质内扩增DNA呈阳性的细胞。通过细胞离心涂片将扩增的细胞转移到载玻片上后,用荧光显微镜观察BCR/ABL cDNA呈阳性的细胞。该技术能够检测低丰度信号并区分不同水平的基因表达。在细胞和上清液中均发现了扩增产物。其分布受到蛋白酶消化条件的严重影响。通过对同一样本提取的mRNA进行BCR/ABL巢式RT-PCR以及对上清液进行再扩增,证实了扩增的特异性。我们已使用该技术研究了10例Ph+ CML患者,并以3名正常受试者作为对照。4例患者在诊断时分别为100% Ph+,细胞遗传学和分子分析时RT-PCR呈阳性。细胞内RT-PCR显示在所有病例中均可观察到残留的非肿瘤细胞。在2例接受α-干扰素(IFN-α)治疗的患者和4例骨髓移植患者中,使用细胞内RT-PCR比较细胞遗传学分析检测到的Ph+阳性水平与表达BCR/ABL转录本的细胞数量。通过这种方式,我们可以估计MRD。该技术的初步应用表明,它能够准确识别转录bcr/abl的细胞,并且在MRD检测中可能具有重要的临床应用价值。